[Toxicities of immune checkpoint inhibitors and their management].
Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité.
Antibodies, Monoclonal
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Cell Cycle Checkpoints
/ drug effects
Drug-Related Side Effects and Adverse Reactions
/ therapy
Humans
Immunologic Factors
/ therapeutic use
Immunotherapy
/ adverse effects
Neoplasms
/ immunology
Patient Care Team
/ organization & administration
Protein Kinase Inhibitors
/ therapeutic use
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
23
6
2020
Statut:
ppublish
Résumé
Immunotherapeutic strategies, notably immune checkpoint inhibitors, have become a standard of care for the treatment of advanced cancers, with a growing spectrum of activity. These monoclonal antibodies target the co-inhibitory signals between tumor cells or antigen-presenting cells and T cells, thereby enhancing antitumour T cell activity. However, the occurrence of immune-related adverse events, that can affect all organ-system, represents a major limiting factor to the clinical development of these antibodies. Management of such toxicity requires a close collaboration between oncologists and organ-specialists, by using glucocorticoids and/or other immunosuppressive therapies, with the common objective not alter anti-tumor response. Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité. L’immunothérapie représente désormais un des piliers de la prise en charge du cancer, notamment avec l’arrivée des inhibiteurs de points de contrôle (checkpoint) immunitaire (ICI, immune checkpoint inhibitors). Ces anticorps thérapeutiques ciblent ces co-signaux inhibiteurs entre cellules tumorales ou cellules présentatrices d’antigènes et lymphocytes T, activant ou réactivant ainsi une immunité cellulaire T anti-tumorale. Mais la survenue d’une toxicité immunologique, qui peut concerner tous les organes, représente le facteur limitant dans le développement clinique de ces anticorps. La gestion de cette toxicité nécessite une collaboration étroite entre oncologues et spécialistes d’organe, et repose sur l’utilisation de corticoïdes et/ou d’autres immunosuppresseurs, avec l’objectif de contrôler la dysimmunité induite sans perdre l’efficacité anti-tumorale.
Autres résumés
Type: Publisher
(fre)
Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité.
Identifiants
pubmed: 31903899
doi: 10.1051/medsci/2019191
pii: msc190197
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
Immunologic Factors
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
949-956Informations de copyright
© 2019 médecine/sciences – Inserm.
Références
Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016 ; 13: 473–486.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 ; 12: 252–264.
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018 29 (suppl 4): iv264–i6.
Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016 ; 60: 12–25.
Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017 ; 19: 3.
Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017 ; 13: 195–207.
Sibaud V, Boulinguez S, Pagès C, et al. Dermatologic toxicities of immune checkpoint inhibitors. Ann Dermatol Venereol 2018 ; 145: 313–330.
Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint inhibitor-induced colitis: A new type of inflammatory bowel disease?. ACG Case Rep J 2017 ; 4: e112.
Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017 ; 28: 2860–2865.
Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: Anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis 2017 ; 11: 1238–1246.
Gentile NM, D’Souza A, Fujii LL, et al. Association between ipilimumab and celiac disease. Mayo Clin Proc 2013 ; 88: 414–417.
De Martin E, Michot J-M, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018 ; 68: 1181–1190.
Su Q, Zhang X-C, Zhang C-G, et al. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: Systematic assessment with meta-analysis. J Immunol Res 2018 ; 2018: 1027323.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018 ; 378: 158–168.
Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 2018 ; 67: 1471–1480.
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017 ; 35: 709–717.
Firwana B, Ravilla R, Raval M, et al. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract 2017 ; 23: 620–624.
Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 2017 ; 2: 709–718.
Moslehi JJ, Salem J-E, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018 ; 391: 933.
Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer 2017 ; 41: 100–110.
Bitton K, Michot J-M, Barreau E, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol 2019 ; 202: 109–117.
Delanoy N, Michot J-M, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019 ; 6: e48–e57.
Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017 ; 28: 368–376.
Johnson DB, Khushalani NI, Puzanov I, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. J Clin Oncol 2017 ; 33: suppl 9019.
Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016 ; 375: 143–153.
Lipson EJ, Bagnasco SM, Moore J, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016 ; 374: 896–898.
Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007 ; 179: 5204–5210.
Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019 ; 7: 106.
Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol 2019 ; 5: 1049–1054.
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016 ; 27: 559–574.
Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst 2017; 109. doi: 10.1093/jnci/djw260.
pii: 10.1093/jnci/djw260
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer 2017 ; 5: 95.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018 ; 36: 1714–1768.
Castinetti F, Albarel F, Archambeaud F, et al. French Endocrine society guidance on endocrine side-effects of immunotherapy. Endocr Relat Cancer 2018 Oct 1; pii: ERC-18-0320.R1.
Gauci M-L, Baroudjian B, Zeboulon C, et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed?. J Hepatol 2018 ; 69: 548–550.
Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2017 ; 77: 393–398.
Roberts J, Smylie M, Walker J, et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 2019 ; 38: 1513–1519.
Ford M, Sahbudin I, Filer A, et al. High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis. Rheumatology 2018 ; 57: 2244–2246.
Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016 ; 2: 1346–1353.
Beardslee T, Draper A, Kudchadkar R. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy. J Oncol Pharm Pract 2019 ; 25: 1275–1281.
Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 2019 ; 25: 551–557.
Khan U, Ali F, Khurram MS, et al. Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 2017 ; 5: 15.
Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014 ; 15: 69–77.
Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017 ; 66: 581–592.
Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 2017 ; 376: 1989–1991.
Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017 ; 35: 3807–3814.
Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009 ; 15: 5591–5598.
Tison A, Quéré G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study. Arthritis Rheum 2019: 10.1002/art.41068.
Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018 ; 36: 2872–2878.
Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018 ; 4: 374–378.